| DIRECT COMPETITOR COMPARISON | |
| KG | CEPH | ELN | FRX | Industry | | Market Cap: | 3.00B | 4.11B | 3.11B | 9.26B | 167.80M | | Employees: | 3,381 | 2,780 | 1,687 | 5,225 | 95 | | Qtrly Rev Growth (yoy): | 19.30% | 10.20% | 6.30% | 4.20% | 20.50% | | Revenue (ttm): | 1.69B | 2.16B | 1.08B | 3.93B | 46.74M | | Gross Margin (ttm): | 68.58% | 82.61% | 50.57% | 78.33% | 68.58% | | EBITDA (ttm): | 533.79M | 703.00M | 26.80M | 881.14M | -6.21M | | Oper Margins (ttm): | 21.23% | 24.96% | -4.49% | 20.40% | 2.25% | | Net Income (ttm): | -472.15M | 280.69M | 51.00M | 730.30M | N/A | | EPS (ttm): | -1.933 | 3.618 | 0.106 | 2.414 | -0.17 | | P/E (ttm): | N/A | 15.21 | 59.62 | 12.71 | 18.61 | | PEG (5 yr expected): | 1.6 | 0.85 | N/A | 1.98 | 1.00 | | P/S (ttm): | 1.78 | 1.90 | 2.87 | 2.35 | 4.40 |
|
| CEPH = Cephalon Inc. | | ELN = Elan Corp. plc | | FRX = Forest Laboratories Inc. | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.80 | 0.00% | 57.49B | 12.39 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.38 | 0.00% | 13.70B | 15.86 | | Genzyme Corp. | GENZ | 50.38 | 0.00% | 13.37B | 28.72 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.96 | 0.00% | 42.26B | 18.16 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.18 | 0.00% | 8.95B | 1024.08 | | Teva Pharmaceutical Industries Limited | TEVA | 53.27 | 0.00% | 46.93B | 48.74 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.05 | 0.00% | 3.93B | 19.10 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.30 | 0.00% | 5.59B | 112.27 | | Pfizer Inc. | PFE | 18.31 | 0.00% | 147.75B | 15.21 | | Johnson & Johnson | JNJ | 63.18 | 0.00% | 174.32B | 13.80 | | GlaxoSmithKline plc | GSK | 42.28 | 0.00% | 107.18B | 13.30 | | Sanofi-Aventis | SNY | 38.63 | 0.00% | 100.87B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.30 | 0.00% | 125.60B | 16.56 | | RHHBY.PK | 41.45 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.25 | 0.00% | 65.61B | 9.09 | | Abbott Laboratories | ABT | 54.24 | 0.00% | 83.90B | 14.70 | | Bristol-Myers Squibb Co. | BMY | 25.16 | 0.00% | 49.84B | 13.02 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | FRX | | Count The Cash At Dell
Tue 5:04pm -
at Investopedia | | • | CEPH | | [$$] Stocks in the Spotlight Monday
Tue 4:47pm -
at Barrons.com | | • | ELN | | 4 Platform Drugmakers to Invest In
Tue 3:20pm -
at Motley Fool | | • | CEPH | | H-P: Analysts' Upgrades, Downgrades
Tue 9:24am -
at TheStreet.com | | • | CEPH | | Cephalon upgraded by Jefferies & Co
Tue 4:00am -
Briefing.com | | • | CEPH | | [$$] Verizon Advances 3%; Chevron, Exxon Rise
Tue 12:05am -
at The Wall Street Journal Online | | • | CEPH | | CEPHALON INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
Mon, Nov 23 -
EDGAR Online | | • | FRX | | Top Takes From RealMoney
Mon, Nov 23 -
at TheStreet.com | | • | FRX | | Icahn Makes Big Moves in Healthcare Stocks
Mon, Nov 23 -
Indie Research | | • | ELN | | UPDATE - HealthCor slams Biogen CEO for outsize pay package
Fri, Nov 20 -
at Reuters | | • | FRX | | MDVN Starts New Alzheimer's Trials
Wed, Nov 18 -
Zacks.com | | • | FRX | | 4-Star Stocks Poised to Pop: Alkermes
Tue, Nov 17 -
at Motley Fool | | • | FRX | | The Hottest Sector for 2010
Mon, Nov 16 -
at Motley Fool | | • | ELN | | Thursday Options Recap
Thu, Nov 12 -
at Seeking Alpha | | • | ELN | | When Rival Drug Makers Compare Notes On Safety Problems
Wed, Nov 11 -
at The Wall Street Journal Online | | • | ELN | | Cramer's Lightning Round - The Only Water Stock Worth Buying (11/10/09)
Wed, Nov 11 -
at Seeking Alpha | | • | ELN | | Lightning Round: Priceline.com, Citigroup, Transocean and More
Tue, Nov 10 -
at CNBC | | • | ELN | | Elan to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Tue, Nov 10 -
Business Wire | | • | ELN | | Successful Pharmaceutical Company Mergers: Abbott Labs Is Leader
Mon, Nov 9 -
Wall Street Transcript | | | All Headlines for these symbols... |
|
|
|
0.04% Nasdaq 
Competitors
